vs
碧迪（BDX）与荷美尔食品（HRL）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是荷美尔食品的1.6倍（$5.3B vs $3.2B），碧迪净利率更高（7.3% vs -1.8%，领先9.0%），荷美尔食品同比增速更快（1.5% vs -0.4%），碧迪自由现金流更多（$549.0M vs $231.4M），过去两年荷美尔食品的营收复合增速更高（3.1% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
荷美尔食品是1891年于美国明尼苏达州奥斯汀成立的跨国食品加工企业，由乔治·A·荷美尔创立。品牌最初主营火腿、香肠等各类畜肉产品的包装与销售，1937年推出斯帕姆午餐肉，上世纪80年代起逐步拓展多元化包装及冷藏食品产品线。
BDX vs HRL — 直观对比
营收规模更大
BDX
是对方的1.6倍
$3.2B
营收增速更快
HRL
高出1.9%
-0.4%
净利率更高
BDX
高出9.0%
-1.8%
自由现金流更多
BDX
多$317.6M
$231.4M
两年增速更快
HRL
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $3.2B |
| 净利润 | $382.0M | $-56.1M |
| 毛利率 | 45.9% | 14.0% |
| 营业利润率 | 10.5% | 0.1% |
| 净利率 | 7.3% | -1.8% |
| 营收同比 | -0.4% | 1.5% |
| 净利润同比 | 24.0% | -125.5% |
| 每股收益（稀释后） | $1.34 | $-0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXHRL
| Q4 25 | $5.3B | $3.2B | ||
| Q3 25 | $5.9B | $3.0B | ||
| Q2 25 | $5.5B | $2.9B | ||
| Q1 25 | $5.3B | $3.0B | ||
| Q4 24 | $5.2B | $3.1B | ||
| Q3 24 | $5.4B | $2.9B | ||
| Q2 24 | $5.0B | $2.9B | ||
| Q1 24 | $5.0B | $3.0B |
净利润BDXHRL
| Q4 25 | $382.0M | $-56.1M | ||
| Q3 25 | $493.0M | $183.7M | ||
| Q2 25 | $574.0M | $180.0M | ||
| Q1 25 | $308.0M | $170.6M | ||
| Q4 24 | $303.0M | $220.2M | ||
| Q3 24 | $400.0M | $176.7M | ||
| Q2 24 | $487.0M | $189.3M | ||
| Q1 24 | $537.0M | $218.9M |
毛利率BDXHRL
| Q4 25 | 45.9% | 14.0% | ||
| Q3 25 | 47.5% | 16.1% | ||
| Q2 25 | 47.8% | 16.7% | ||
| Q1 25 | 42.8% | 15.9% | ||
| Q4 24 | 43.2% | 16.6% | ||
| Q3 24 | 45.7% | 16.8% | ||
| Q2 24 | 46.2% | 17.4% | ||
| Q1 24 | 45.7% | 17.0% |
营业利润率BDXHRL
| Q4 25 | 10.5% | 0.1% | ||
| Q3 25 | 11.8% | 7.9% | ||
| Q2 25 | 16.0% | 8.6% | ||
| Q1 25 | 10.4% | 7.6% | ||
| Q4 24 | 8.8% | 9.4% | ||
| Q3 24 | 11.4% | 8.2% | ||
| Q2 24 | 12.1% | 8.7% | ||
| Q1 24 | 14.5% | 9.5% |
净利率BDXHRL
| Q4 25 | 7.3% | -1.8% | ||
| Q3 25 | 8.4% | 6.1% | ||
| Q2 25 | 10.4% | 6.2% | ||
| Q1 25 | 5.8% | 5.7% | ||
| Q4 24 | 5.9% | 7.0% | ||
| Q3 24 | 7.4% | 6.1% | ||
| Q2 24 | 9.8% | 6.6% | ||
| Q1 24 | 10.6% | 7.3% |
每股收益（稀释后）BDXHRL
| Q4 25 | $1.34 | $-0.10 | ||
| Q3 25 | $1.71 | $0.33 | ||
| Q2 25 | $2.00 | $0.33 | ||
| Q1 25 | $1.07 | $0.31 | ||
| Q4 24 | $1.04 | $0.41 | ||
| Q3 24 | $1.37 | $0.32 | ||
| Q2 24 | $1.68 | $0.34 | ||
| Q1 24 | $1.85 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $703.6M |
| 总债务越低越好 | — | $2.9B |
| 股东权益账面价值 | $25.3B | $7.9B |
| 总资产 | $54.8B | $13.4B |
| 负债/权益比越低杠杆越低 | — | 0.36× |
8季度趋势，按日历期对齐
现金及短期投资BDXHRL
| Q4 25 | $740.0M | $703.6M | ||
| Q3 25 | $641.0M | $630.7M | ||
| Q2 25 | $735.0M | $699.0M | ||
| Q1 25 | $667.0M | $866.4M | ||
| Q4 24 | $711.0M | $766.6M | ||
| Q3 24 | $1.7B | $561.9M | ||
| Q2 24 | $4.5B | $1.5B | ||
| Q1 24 | $2.3B | $981.9M |
总债务BDXHRL
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $2.9B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $2.4B |
股东权益BDXHRL
| Q4 25 | $25.3B | $7.9B | ||
| Q3 25 | $25.4B | $8.1B | ||
| Q2 25 | $25.5B | $8.0B | ||
| Q1 25 | $25.2B | $8.0B | ||
| Q4 24 | $25.2B | $8.0B | ||
| Q3 24 | $25.9B | $7.9B | ||
| Q2 24 | $25.9B | $7.9B | ||
| Q1 24 | $25.6B | $7.8B |
总资产BDXHRL
| Q4 25 | $54.8B | $13.4B | ||
| Q3 25 | $55.3B | $13.5B | ||
| Q2 25 | $54.9B | $13.4B | ||
| Q1 25 | $54.5B | $13.4B | ||
| Q4 24 | $54.7B | $13.4B | ||
| Q3 24 | $57.3B | $13.1B | ||
| Q2 24 | $55.6B | $14.1B | ||
| Q1 24 | $54.2B | $13.5B |
负债/权益比BDXHRL
| Q4 25 | — | 0.36× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | 0.36× | ||
| Q2 24 | — | 0.36× | ||
| Q1 24 | — | 0.30× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $322.9M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $231.4M |
| 自由现金流率自由现金流/营收 | 10.5% | 7.3% |
| 资本支出强度资本支出/营收 | 2.1% | 2.9% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $2.6B | $534.3M |
8季度趋势，按日历期对齐
经营现金流BDXHRL
| Q4 25 | $657.0M | $322.9M | ||
| Q3 25 | $1.4B | $156.7M | ||
| Q2 25 | $1.2B | $56.4M | ||
| Q1 25 | $164.0M | $309.2M | ||
| Q4 24 | $693.0M | $408.6M | ||
| Q3 24 | $1.2B | $218.0M | ||
| Q2 24 | $1.3B | $236.1M | ||
| Q1 24 | $514.0M | $404.0M |
自由现金流BDXHRL
| Q4 25 | $549.0M | $231.4M | ||
| Q3 25 | $1.0B | $84.5M | ||
| Q2 25 | $1.0B | $-18.6M | ||
| Q1 25 | $35.0M | $237.0M | ||
| Q4 24 | $588.0M | $324.8M | ||
| Q3 24 | $882.0M | $152.5M | ||
| Q2 24 | $1.1B | $176.2M | ||
| Q1 24 | $380.0M | $356.8M |
自由现金流率BDXHRL
| Q4 25 | 10.5% | 7.3% | ||
| Q3 25 | 17.0% | 2.8% | ||
| Q2 25 | 19.0% | -0.6% | ||
| Q1 25 | 0.7% | 7.9% | ||
| Q4 24 | 11.4% | 10.4% | ||
| Q3 24 | 16.2% | 5.3% | ||
| Q2 24 | 22.4% | 6.1% | ||
| Q1 24 | 7.5% | 11.9% |
资本支出强度BDXHRL
| Q4 25 | 2.1% | 2.9% | ||
| Q3 25 | 6.0% | 2.4% | ||
| Q2 25 | 3.2% | 2.6% | ||
| Q1 25 | 2.4% | 2.4% | ||
| Q4 24 | 2.0% | 2.7% | ||
| Q3 24 | 5.4% | 2.3% | ||
| Q2 24 | 3.6% | 2.1% | ||
| Q1 24 | 2.7% | 1.6% |
现金转化率BDXHRL
| Q4 25 | 1.72× | — | ||
| Q3 25 | 2.75× | 0.85× | ||
| Q2 25 | 2.12× | 0.31× | ||
| Q1 25 | 0.53× | 1.81× | ||
| Q4 24 | 2.29× | 1.86× | ||
| Q3 24 | 2.94× | 1.23× | ||
| Q2 24 | 2.66× | 1.25× | ||
| Q1 24 | 0.96× | 1.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
HRL
| Retail Segment | $1.9B | 60% |
| Foodservice Segment | $1.1B | 34% |
| Other | $174.7M | 5% |
